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biochemical data on admission were recorded prospectively 
in each cohort, with prospective adjudication of outcomes.
Results Positive and negative linear relationships between 
90-day mortality and sK+ above 4.5 mmol/L (hyperkalemia) 
and below 3.5 mmol/L (hypo-kalemia) were observed. Haz-
ard ratio for death was 1.46 [1.34–1.58] for hyperkalemia 
and 1.22 [1.06–1.40] for hypokalemia. In a fully adjusted 
model, only hyperkalemia remained associated with mor-
tality (HR 1.03 [1.02–1.04] for each 0.1 mmol/l change of 
sK+ above 4.5 mmol/L). Interaction tests revealed that the 
association between hyperkalemia and outcome was sig-
nificantly affected by chronic medications. The association 
between hyperkalemia and mortality was absent for patients 
treated with beta blockers and in those with preserved renal 
function.
Conclusions In patients with AHF, sK+ > 4.5 mmol/L 
appears to be associated with 90-day mortality. 
Abstract 
Background The interaction between chronic medications 
on admission and the association between serum potassium 
level and outcome in patients with acute heart failure (AHF) 
are unknown.
Methods Observational intercontinental study of patients 
admitted with AHF. 15954 patients were included from 12 
cohorts in 4 continents. Main outcome was 90-day mortal-
ity. Clinical presentation (medication use, hemodynam-
ics, comorbidities), demographic, echocardiographic, and 
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B-blockers have potentially a protective effect in the setting 
of hyperkalemia.
Keywords Mortality · Potassium · B-blockers · Heart 
failure · Renal failure
Introduction
Patients hospitalized for acute heart failure (AHF) have a 
high risk of death and rehospitalization [1]. Among meta-
bolic disorders, serum potassium level has been a factor of 
interest in this setting. Serum potassium (sK+) is under the 
control of several factors that can be altered in patients with 
AHF including renal function or activation of renin–angio-
tensin–aldosterone system [2, 3]. Hypo- and hyperkalemia 
might, therefore, represent a direct risk of lethal cardiovascu-
lar complication but also an indirect biomarker of the sever-
ity of the underlying disease (i.e., neurohormonal activation 
or renal dysfunction) [4]. Several treatments administered 
to heart failure patients also interact with sK+ (e.g., non-
potassium sparing diuretics, angiotensin-converting enzyme 
inhibitors or angiotensin receptor blockers, beta blockers or 
mineralocorticoid receptor antagonists aldosterone) and lead 
to a risk of hyperkalemia that may curb their prescription 
[5–9]. Furthermore, very little data are yet available on the 
interaction between chronic medications and dyskalemia on 
prognosis [10]. The objective of this study was to describe 
the association between sK+ at hospital admission and 
90-day mortality in patients with AHF, and the interaction 
of treatment on this association.
Methods
The study population was derived from the GREAT reg-
istry, an international, multicenter, prospective observa-
tional cohort of adult patients with AHF as the main diag-
nosis at hospital admission. Details on the constitution 
of the GREAT registry have been previously described 
in detail [11, 12]. We defined patients as eligible if they 
were identified as presenting with AHF and had their 
potassium level measured on arrival at the emergency 
department. All patients had AHF according to the Euro-
pean Society of Cardiology guidelines. Both patients with 
new-onset (i.e., no history) heart failure (HF) and with 
decompensated chronic HF were included. Small cent-
ers (which included < 250 patients) were not included for 
the homogeneity of the cohort. The principal investiga-
tors for each study submitted hospital patient-level data 
from admission. 21,865 patients are part of the GREAT 
network registries from 19 centers in 16 countries of 4 
continents. After serial exclusion of patients for out-
come and serum K+ on admission missing data and from 
small recruitment centers, 15,954 patients formed the 
final cohort (Supplemental Digital Content—Fig.  1). 
Clinical details of presentation (medication use, hemo-
dynamics, comorbidities), as well as demographic, echo-
cardiographic, and biochemical data on admission were 
recorded prospectively in each cohort, with prospective 
adjudication of outcomes. Estimated glomerular filtration 
rate (eGFR) was calculated by the Modified Diet in Renal 
Disease formula. Normal range of potassium level across 
centers were 3.5 (CI 95% 3.5–3.5) and upper limit of 5.1 
(CI 95% 4.9–5.5) mmol/L. Outcomes were assessed at 90 
days by medical chart review at each institution. Local 
institutional review boards/ethics committees approved 
all study procedures.
Statistical analysis
Baseline demographic characteristics were expressed as 
median and interquartile range or frequency, and were 
compared using nonparametric techniques for continuous 
data (e.g., Wilcoxon or Kruskal–Wallis test) or chi-square 
testing for categorical covariates. The primary outcome 
of our study was all-cause mortality at 90 days post-
discharge. Survival time was calculated from the date of 
admission until the date of death, or the last follow-up. 
Survival time was calculated from the date of admission 
until the date of death or last follow-up. Univariate and 
multivariate Cox proportional hazards regression mod-
els were used to estimate effects for each covariate on 
mortality. Variables included in the multivariate models 
for adjustment were gender, age, hyponatremia (defined 
as natremia at admission < 136 mmol/L), hyperglycemia 
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(defined as glycemia at admission > 7 mmol/L), eGFR 
(dichotomized around 60 ml/min/1.73 m²), systolic and 
diastolic blood pressure at presentation, diabetes, history 
of heart failure, coronary artery disease and history of 
atrial fibrillation. We also took into account the region 
of origin. These factors were chosen because of their pre-
viously published association with outcome in patients 
with ADHF and their statistical association with mortality 
in univariate analysis in the present cohort. Proportional 
hazards assumptions were verified. The log-linearity of 
the effect of kalemia at admission was assessed in all 
patients and subgroups of patients for 90-day mortality 
using restricted cubic spline function. Hyper- and hypoka-
lemia cut-off values were not predefined but prospec-
tively defined as the value of kalemia associated with the 
lowest mortality ± 0.5 mmol/L. Our study was composed 
of a worldwide sample of patients with AHF; given that 
patients were included from various centers, a potential 
cluster effect was taken into account in the models. In 
addition, several subgroups were pre-defined based on 
kidney function at admission and on chronic treatment 
of the patients. Three subgroups of kidney function were 
defined as eGFR ≥ 60 ml/min/1.73m², eGFR < 60 ml/
min/1.73m² and eGFR < 30 ml/min/1.73m². In addition, 
several subgroups were pre-defined based on kidney func-
tion and on chronic treatment. The chronic treatments 
considered were RASi (angiotensin-converting enzyme 
inhibitors, ACE-i; angiotensin receptor blockers, ARB; 
beta blockers, BB; mineralocorticoid receptor antago-
nists, MRA) and loop diuretics. Last, the association 
between kalemia and mortality was assessed separately 
in patients with preserved left ventricular ejection frac-
tion (LVEF) and in those with altered LVEF.
We adjusted for all covariates specified in the main multi-
variable Cox regression model for these subgroup analyses. 
Statistical analyses were performed using R (version 2.15.0, 
R Foundation for Statistical Computing, Vienna, Austria). 




Patients presenting with hyperkalemia, as defined by 
serum potassium > 4.5 mmol/L, had lower glomerular 
filtration rate and more frequently had a history of heart 
failure. They had higher plasma brain natriuretic peptide 
on admission and hyperglycemia, both prognostic fac-
tors of poor outcome in heart failure patients suggest-
ing more advanced heart failure compared to patients 
admitted with hypo- or normokalemia. Hemodynamics 
parameters were slightly but significantly different in 
patients with hyperkalemia with lower systolic and dias-
tolic blood pressure and lower left ventricular ejection 
fraction. Characteristics of patients are presented in 
Table 1.
Association between serum potassium level and 90-day 
mortality
Figure 1 shows the linear relationships between 90-day 
mortality and hyper- (above 4.5  mmol/L) and hypo-
kalemia (below 3.5  mmol/L). The hazard ratio for 
death was 1.46 [1.34–1.58] for hyperkalemia and 1.22 
[1.06–1.40] for hypokalemia, both versus normokalemia 
(Fig. 2). However, in a fully adjusted model taking into 
account potential confounding factors associated with 
poor outcome (see methods for details) only hyperkalemia 
remained associated with mortality, 1.03 [1.02–1.04] 
for 0.1 mmol/l changes of sK+ above 4.5 mmol/L and 
not hypokaliemia (HR 1.03 [0.98–1.09] for 0.1 mmol/l 
changes of sK+ below 3.5 mmol/L) (Table 2).
Influence of LVEF or renal function on the relationship 
between increased sK+ and short-term outcome
In univariate analysis, an association between hyper-
kalemia and mortality exists only in patients with 
eGFR < 60 ml/min/1.73 m2. The threshold of the associa-
tion between potassium level and poor outcome appears to 
be higher (i.e., 5 mmom/L) in patients with severe renal 
dysfunction (eGFR < 30 ml/min/1.73 m2) (Fig. 3). LVEF 
had no impact on the incidence of hyperkalemia on asso-
ciation with outcome.
Influence of chronic heart failure medications 
on the relationship between increased sK+ 
and outcome
Patients’ treatment rates with ACE-i, ARB, MRA, and BB 
were no different as compared with normo-, hypo- or hyper 
kalemia (Table 1). However, patients with hyperkalemia 
received diuretics and nitrate more often, as would be con-
sistent with more advanced heart failure.
Figure 3 shows that the association between hyperkalemia 
and mortality remained when acute heart failure patients 
were treated or not with oral RASi, MRA or loop diuret-
ics on admission, but was not observed when patients were 
treated with oral BB. Effects of heart failure medications on 
the association between low sK+ and short-term outcomes 
are shown in Table 2. Table 2 confirms that, even after 
adjustment for potential confounding factors, the association 
between hyperkalemia and short-term mortality remained 
217Clin Res Cardiol (2018) 107:214–221 
1 3
significant with all heart failure medications except oral BB 
on admission.
Discussion
In this study, we observed that sK+ was associated with 
90-day mortality in a U-shaped curve linking mortal-
ity and sK + in acute heart failure patients. However, 
only hyperkalemia (> 4.5 mmol/L), but not hypokalemia 
(< 3.5 mmol/L), remained a risk factor of short-term death 
after adjustment for potential confounding factors. Patients 
with normal renal function seem not to be exposed to risks 
of hyperkalemia, while most chronic heart failure medica-
tions did not alter the negative association between outcome 
and high sK+, except in patients on BB for whom high sK+ 
was not a risk factor of short-term death.
Association between hypokalemia and outcome
Low sK+ has long been recognized as a risk of death in 
heart failure patients. Korgaonkar et al [13], in a cohort 
of 820 patients with chronic renal failure observed an 
increased in mortality risk with hypokalemia. In this line, 
Ahmed et al [10], observed an increased risk of mortality 
in heart failure patients with low sK+. Interestingly, scales 
have been proposed for risk stratification (7- and 30-day 
mortality, respectively) of patients with AHF at emergency 
departments arrival, including potassium among the varia-
bles needed to calculate the score in a very similar way that 
Table 1  Characteristics of patients included in the study,
p values correspond to chi-2 or Kruskal–Wallis test, as appropriate
BMI body mass index, COPD chronic obstructive pulmonary disease, GFR glomerular filtration rate, HFrEF heart failure with reduced left ven-
tricular ejection fraction, Afib atrial fibrillation, CAD coronary artery disease, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin 
receptor blockers, BB BBs, MRA mineralocorticoids receptors antagonists, ASA acetylsalicylic acid, SBP systolic blood pressure, DBP diastolic 
blood pressure, HR heart rate, LVEF left ventricular ejection fraction, Hb hemoglobin, BNP B-type natriuretic peptide
Variables All patients Normokalemia (3.5–








Age 72 (61.4 to 80) 71.5 (60.6 to 80) 71.8 (60.8 to 79.9) 73.1 (63.3 to 80.7) < 0.0001
Female gender 6942 (43.5) 4271 (42.7) 681 (47.9) 1990 (44) 0.00063
BMI 26.3 (23.2 to 30.1) 26.3 (23.4 to 30) 26.4 (23.2 to 30.1) 26.1 (22.9 to 30.2) 0.47
COPD, n(%) 2245 (15.2) 1357 (14.7) 197 (14.5) 691 (16.3) 0.041
Hypertension, n(%) 10,520 (66.6) 6447 (65) 963 (69) 3110 (69.4) < 0.0001
Previous HF, n(%) 7276 (46.5) 4417 (45) 580 (41.5) 2279 (51.4) < 0.0001
AFib, n(%) 4366 (28.1) 2717 (27.8) 392 (28.6) 1257 (28.5) 0.66
CAD, n(%) 7954 (50.2) 4965 (49.9) 718 (50.8) 2271 (50.7) 0.63
Diabetes, n (%) 6687 (42.2) 3970 (39.9) 510 (36.4) 2207 (49.2) < 0.0001
BB, n (%) 6015 (39.7) 3823 (40.1) 541 (40.1) 1651 (38.4) 0.16
ACEi, n (%) 7283 (49.1) 4600 (49.4) 621 (47.5) 2062 (48.9) 0.42
ARB, n (%) 2985 (20.1) 1911 (20.5) 227 (17.4) 847 (20.1) 0.03
Diuretics, n (%) 7156 (58.8) 4419 (57.2) 618 (58.2) 2119 (62.6) < 0.0001
MRA, n (%) 3877 (25.9) 2436 (25.8) 328 (25.3) 1113 (26.1) 0.83
Nitrate, n (%) 2000 (17.4) 1245 (17.2) 141 (13.7) 614 (19) 0.00034
ASA, n (%) 4863 (43.1) 3022 (42.5) 416 (41.1) 1425 (45) 0.026
Statin, n (%) 3716 (34.6) 2326 (34.4) 318 (32.1) 1072 (35.9) 0.074
SBP (mmHg) 130 (110 to 153) 132 (113–154) 131 (110–155) 130 (110 to 150) < 0.0001
DBP (mmHg) 79 (66 to 90) 80 (67–90) 80 (67–90) 77 (65–90) < 0.0001
HR (bpm) 88 (73–105) 88 (73–105) 89 (75–107) 86 (72–104) 0.00078
LVEF < 40%, n (%) 4577 (42.8) 2881 (42.7) 440 (43.3) 1256 (42.6) 0.93
Hb, g/dl 12.8 (11.2–14.2) 13 (11.4–14.3) 12.7 (11.2–14.2) 12.3 (10.7–14) < 0.0001
Na+ (mmol/L) 138 (135–141) 138 (135.8–141) 139 (135–141) 137 (134–140) < 0.0001
eGFR (ml/min/1.73 m2) 53.8 (38.7–71.1) 57.7 (43.1–74.4) 57.6 (44.1–74.8) 43.4 (29.1–60.1) < 0.0001
Glucose (mmol/L) 9.9 (6.5–88) 9.4 (6.5–80) 10 (6.7–62.2) 11.3 (6.8–101) < 0.0001
BNP (pg/mL) 913.5 (415.8–1739.2) 840 (389–1637) 905 (388.8–1697.8) 1118 (519–2105.3) < 0.0001
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we have found in the present study: both confer a worse 
prognosis, with hyperkalemia having a most detrimental 
impact on it [14]. In addition, association between sK+ 
< 4 mmol/L and prognosis was found in two large cohorts 
of chronic heart failure patients with chronic renal failure 
after matching with a propensity score [15, 16], suggesting 
that hypokalemia could be a marker of severity of heart 
failure rather than a causal factor of death. This assumption 
is reinforced by the fact that potassium-sparing treatments 
such MRA may improve survival, unlike potassium supple-
mentation [5, 17]. Others, however, raised concerns regard-
ing risk of arrhythmia, sudden deaths and vascular effects 
with hypokalemia [18]. The non-significant association 
between hypokalemia and mortality after adjustment for 
confounding factors in our study also strongly suggested 
that hypokalemia may represent a marker of disease sever-
ity rather than an independent factor of poor outcome in 
heart failure.
Association between hyperkalemia and outcome
Less common are studies linking hyperkalemia and 
the risk of death in heart failure patients. In our study, 
we observed that the sK+ threshold for poor out-
come is lower than usually proposed as a definition of 
hyperkalemia. The risk of dying increased by 3% per 
0.1 mmol/L increase in serum potassium level which 
appears clinically significant. This suggests that defini-
tion for hyperkalemia with sK+ > 5–5.5 mmol/L might 
be too restrictive [18]. Ahmed et al. have demonstrated 
an increased risk of death with sK+ > 5–5.5 mmol/L in 
a cohort of chronic heart failure after adjustment with 
a propensity score analysis [19]. Altered renal function 
at admission appears to affect the relationship between 
high sK+ and mortality in 2 ways. First, the relationship 
between high sK+ and increased short-term mortality was 
only seen in acute heart failure patients with impaired 
renal function (eGFR < 60  ml/min/1.73  m2). Second, 
the presence of severe renal impairment (eGFR < 30 ml/
min/1.73 m2) appeared to right shift the slope of the asso-
ciation between sK+ and mortality (about 0.5 mmol/L). 
Those findings could be related to hyperkalemia toler-
ance when sK+ is chronically elevated. The association 
between high sK+ and mortality remained after adjust-
ment for potential confounding factors suggesting that 
serum potassium greater than 4.5 mmol/L is a risk factor 
of short-term death in acute heart failure.
Fig. 2  Kaplan–meier curves showing survival curves in patients 
with hypokalemia (K+ < 3.5  mmol/L), normokalemia (K+ 3.5–
4.5 mmol/L) and hyperkalemia (K+ > 4.5 mmol/L)
Fig. 1  Distribution of serum 
potassium level on admission 
(a) and relationship between 
potassium serum level on 
admission and probability 
of death at 90 days. Results 
presented in median (IC 95%). 
The U-shape curve indicated an 
increased risk of death associ-
ated with both hypo- and hyper-
kalemia with a narrow range of 
K+ serum (3.5–4.5 mmol/L) 
centered on sK+ = 4 mmol/L 
associated with the lowest risk 
of death (b)
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Impact of chronic medications on the association 
between serum potassium level and outcome
Significant information provided by our study is the influ-
ence of chronic heart failure therapies, most of which are 
known to affect sK+, on the relationship between mor-
tality and sK+. Several authors have shown that chronic 
treatment by MRA is associated with a moderate increase 
in sK+ in heart failure patients [2, 20]. Likewise, chronic 
administration of ACE inhibitors or ARB was already 
described as a risk factor of hyperkalemia in heart failure 
patients. The consequences of a rise of sK+ on the prog-
nosis of patients with acute heart failure, however, have 
not been thoroughly explored.
In our study, taking into account potential confound-
ing factors associated with poor outcome, only hyper-
kalemia remained associated with mortality in patients 
with altered eGFR. Our study also showed that though 
no causal relationship can be drawn from this observa-
tional data, treatment with BB might counteract the det-
rimental effect of dyskalemia on outcome, suggesting a 
protective effect of BB toward hyperkalemia. This might, 
at least partly explain, the striking benefits of BB on 
short-term outcome in AHF patients previously described 
[21, 22]. Our study has several limitations. First, we 
cannot exclude pseudo-hyperkalemia in some patients. 
However, the size of the cohort reduces the risk of error 
when interpreting the results in reducing this noise. Only 
renal function and sK+ values at hospital admission 
were available and the values prior to admission were 
unknown. Also, the mechanism of hyperkalemia (i.e., 
transfer or renal excretion deficit) could not be explored. 
It is possible that mechanisms influence the progno-
sis of hyperkalemia. We acknowledge that adhesion to 
guidelines regarding treatment of heart failure was low, 
especially regarding the use of B-blockers (only 40% of 
patients were treated with B-blockers) [23]. This obser-
vation was similar to recently published low adherence 
to guidelines in heart failure patients [24–26]. Potas-
sium intake was not available in this registry. Finally, 
therapeutic strategies implemented during hospitalization 
and changes in serum potassium during the hospital stay 
were not known. However, it should be noted that Khan 
et al. studied the impact on prognosis relative to changes 
in serum potassium during hospitalization among AHF 
patients from the EVEREST trial, and did not detect any 
impact on mortality [20].
To conclude, after adjustment we observed an associa-
tion between admission hyperkalemia > 4.5 mmol/L and 
90 day mortality in AHF patients, suggesting that cur-
rent definitions of hyperkalemia might be too restrictive. 
This association was not observed in patients treated 
with B-Blockers, even after adjustment on potential 
Table 2  Hazard ratio of hyper and hypokalemia for 90-day mortality
Statistically significant values are appear in bold
Hazard ratio of hyper and hypokalemia for 90 days mortality after adjustment for potential confounding factors (see text for details) according to 
estimated glomerular filtration rate (eGFR), heart failure status (HFrEF Heart failure with reduced ejection fraction, HRpEF heart failure with 
preserved ejection fraction) and treatments on admission (RASi renin–angiotensin system inhibitors, MRA mineralocorticoids receptors antago-
nists). Note than thresholds for hyper and hypokalemia were adjusted for each condition based on the relationship between sK+, GFR and treat-
ments (Fig. 3)
* < 0.05
Sub-groups “Normal” range of 
kalemia
OR for each 0.1 mmol/l 
below the lower limit
pinteraction OR for each 0.1 mmol/l 
above the upper limit
pinteraction
All patients (n = 15 954) 3.5–4.5 1.03 [0.98–1.09] – 1.03 [1.02–1.04]* –
eGFR > = 60 (n = 5332) 3.3–4.3 1.09 [1.03–1.15] 0.005 1.02 [0.99–1.04] 0.04
eGFR < 60 (n = 7893) 3.5–4.5 1.03 [0.97–1.09] 1.03 [1.02–1.04]*
eGFR < 30 (n = 1858) 4.0–5.0 1.05 [1.03–1.07]* 1.03 [1.01–1.05]*
HFrEF (n = 4577) 3.2–4.2 1.14 [1.08–1.21] 0.01 1.02 [1.01–1.03]* 0.04
HFpEF (n = 8128) 3.55–4.55 1.02 [0.96–1.08] 1.02 [1.01–1.03]*
No RASi (n = 5837) 3.5–4.5 1.05 [0.99–1.12] < 0.0001 1.02 [1.00–1.04]* 0.005
RASi (n = 8995) 3.5–4.5 0.98 [0.94–1.02] 1.03 [1.02–1.04]*
No BB (n = 9154) 3.4–4.5 1.08 [1.01–1.16]* 0.04 1.03 [1.02–1.04]* 0.009
BB (n = 6015) 3.6–4.6 0.99 [0.92–1.06] 1.01 [0.95–1.08]
No diuretic (n = 5020) 3.3–4.3 1.22 [1.07–1.38]* 0.001 1.03 [1.01–1.05]* < 0.0001
Diuretic (n = 7156) 3.5–4.5 1.05 [1.02–1.08]* 1.04 [1.03–1.05]*
No MRA (n = 11,102) 3.5–4.5 1.03 [0.99–1.07] 0.91 1.03 [1.02–1.05]* < 0.0001
MRA (n = 3877) 3.5–4.5 1.02 [0.91–1.13] 1.01 [1.00–1.03]*
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Fig. 3  Graphical representa-
tion of the relationship between 
serum potassium level and risk 
of death according to renal 
function at admission (a), 
diuretics (b), RASi (c), left 
ventricular ejection fraction 
(d), mineralocorticoid receptors 
antagonists (e) and B-blockers 
(f). eGFR estimated glomerular 
filtration rate, HFrEF heart fail-
ure with reduced left ventricular 
ejection fraction, HFpEF heart 
failure with preserved left 
ventricular ejection fraction, 
RASi renin angiotensin aldos-
terone system inhibitors (i.e., 
angiotensin-converting enzyme 
inhibitors and angiotensin 
receptor blockers); BB BBs, 
MRA mineralocorticoid receptor 
antagonists
221Clin Res Cardiol (2018) 107:214–221 
1 3
confounding factors. B-blockers may have potentially a 
protective effect in the setting of hyperkalemia.
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